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Interindividual variability in drug metabolism is an important cause of adverse drug reactions and variability in drug 
efficiency. Polymorphisms of cytochrome P450 (CYPs) genes have a significant effect on drug metabolism and toxicity. 
This review brings an update about how genetic polymorphisms of CYP2C8 and CYP2C9 enzymes affect the disposition 
and clinical outcomes of ibuprofen and diclofenac, two of the most common pain relievers. The most common side effects 
associated with the influence of CYP2C8*3 and CYP2C9*2*3 variants on ibuprofen and diclofenac pharmacokinetics 
are hepatotoxicity and gastrointestinal bleeding. CYP genotyping may therefore identify patients at increased risk of these 
adverse reactions, and these patients could have their doses adjusted or start receiving another NSAID that does not share 
the same metabolic pathways with ibuprofen or diclofenac. However, before genotyping is introduced into regular clinical 
practice, more research is needed to evaluate the effectiveness of this strategy in improving treatment with ibuprofen and 
diclofenac.
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Since its completion, the Human Genome Project has 
given a s trong boost  to  pharmacogenetic  and 
pharmacogenomic research of variability in drug effects 
based on individual genetic make-up (1). Genetic factors 
affect the pharmacokinetic profile of drugs and change their 
efficacy and toxicity properties (2). The final goal of 
pharmacogenomics is to make use of genetic testing to 
optimise pharmacotherapy and adjust it to individual needs 
(3).
Nonsteroidal anti-inflammatory drugs (NSAIDs) are 
among the most commonly prescribed medications in 
developed countries. According to the American 
Gastroenterological Association, more than 30 million 
Americans use NSAIDs every day (data available at http://
www.webmd.com/arthritis/features/making-decision-on-
nsaids).
NSAIDs inhibit the ability of cyclooxygenase (COX) 
to produce prostaglandins from arachidonic acid, which in 
turn suppresses inflammation in most patients (4, 5). 
NSAIDs are prescribed as analgesics, anti-inflammatory, 
and antipyretic agents for a number of indications. 
Ibuprofen and diclofenac are often prescribed as NSAIDs 
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of choice in managing rheumatoid arthritis, post-operative 
pain, and chronic pain associated with cancer. Both are 
metabolised by polymorphic phase I metabolic enzymes, 
predominantly cytochromes P450 (CYPs) and by phase II 
UDP-glucuronosyltransferases (6). Phase III polymorphic 
drug transporters have also been evidenced to modulate 
their toxicity and efficacy (7, 8).
This review brings an update about the association 
between genetic polymorphisms of CYP enzymes and 
individual differences in ibuprofen and diclofenac 
disposition and clinical outcomes.
Ibuprofen metabolism
Ibuprofen is a racemic mixture of the (S)-(+)- and (R)-
(-)-  enantiomers administered through several 
pharmaceutical formulations. (S)-(+)-ibuprofen is the active 
enantiomer, both in vitro and in vivo (9). Nearly 65 % of 
R-(-)-ibuprofen is inverted to the (S)-(+)- enantiomer in the 
liver and some of it is pre-systemically inverted in the gut 
in the presence of acylCoA thioester, with alpha-methylacyl-
coenzyme A racemase (AMACR) acting as the catalyst (9, 
10).
(S)-(+)-and (R)-(-)-ibuprofen are promptly metabolised 
by phase I detoxification enzymes in human liver (10). The 
metabolic pathways of its enantiomers differ significantly. 
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2S(+)-ibuprofen is metabolised mostly by CYP2C9 while 
R-(-)-IBU is metabolised mainly via CYP2C8 (11, 12).
The main primary metabolites of ibuprofen are hydroxy 
metabolites 1-OH-IBU, 2-OH-IBU, and 3-OH-IBU and the 
carboxy metabolite (carboxy-ibuprofen) (10), but none has 
important pharmacological activity (9, 13, 14). The phase 
II metabolism of ibuprofen involves glucuronidation by 
uridine 5’-diphospho-glucuronosyltransferase (UGT) 
isoenzymes 1A9, 1A3, 2B1, and 2B7, of which UGT2B7 
has the highest in vitro activity with racemic ibuprofen (15). 
Most of ibuprofen is metabolised and the major route of 
ibuprofen excretion is through the kidney and just a small 
percentage of the parent drug is excreted unchanged in 
urine.
The risk of toxicity is related to the binding (covalent 
type) of ibuprofen-glucuronide to plasma proteins, which 
is the highest in patients with renal impairment (16). 
Thiolated derivatives of ibuprofen (less than 1 %) are 
considered reactive and may cause adverse reactions (17).
Diclofenac metabolism
Diclofenac is rapidly and completely absorbed from 
human intestines after oral administration and is detoxified 
through hydroxylation and glucuronidation (18). Its 
oxidation to 4’- and 5’-hydroxylated derivatives is catalysed 
by CYP2C9 and CYP3A4 (19), whereas glucuronidation 
is catalysed by UGT2B7 (20-22). The oxidised metabolites 
are mainly excreted through the kidney (65 % of diclofenac), 
while the rest (35 %) as acyl glucuronide is excreted through 
the bile (23, 24). Oral bioavailability of diclofenac drops 
to 50-60 % of the applied dose as a result of first-pass 
metabolism and low enterohepatic circulation. After 
excretion into the intestines, diclofenac acyl glucuronide 
undergoes hydrolysis by intestinal bacteria enzymes called 
β-glucuronidases. As a result of its reabsorption, 
enterohepatic recirculation of diclofenac is high (25). Acyl 
glucuronides of diclofenac are chemically unstable 
compounds that can undergo epimerisation through acyl 
migration to the 2-, 3-, or 4-O-glucuronide, particularly in 
the alkaline medium of the bile. These isomers are believed 
to resist deconjugation by β-glucuronidases (26).
Transporters may play an important role in the drug’s 
fate in human organism. Using a mice model, Lagas et al. 
(27) have shown that multidrug resistance proteins 2 
(MRP2/ABCC2) and 3 (MRP3/ABCC3) as well as breast 
cancer resistance protein (BCRP/ABCG2) have a significant 
role in the pharmacokinetics of diclofenac glucuronides. In 
their study, MRP2/ABCC2 and BCRP significantly changed 
biliary excretion of diclofenac glucuronides, while MRP3/
ABCC3 was the main efflux transporter from the liver to 
blood. Concurrent loss of function of MRP2/ABCC2, 
MRP3/ABCC3, and BCRP/ABCG2 resulted in significant 
accumulation of reactive diclofenac glucuronides in the 
mice liver and acute but mild toxicity.
Acquired or hereditary deficiency of ABCC2, known 
as Dubin-Johnson syndrome in humans, can cause an 
increased concentration of bilirubin glucuronides (28). As 
diclofenac shares the same ABCC2 transporter pathway, it 
should be prescribed to these individuals with caution to 
avoid adverse reactions to diclofenac, hepatotoxicity in 
particular.
Genetic polymorphisms of CYP enzymes
Interindividual variability as a consequence of 
polymorphisms in CYP genes is highly associated with the 
level of drug toxicity (29, 30). Among over fifty CYP 
enzymes, the human CYP2C family accounts for 18-30 % 
of the total content of CYP450 enzymes in the human liver 
and is responsible for the metabolism of nearly one fifth of 
the commonly prescribed drugs such angiotensin-II 
antagonists, NSAIDs, oral antidiabetics, antiepileptics, oral 
anticoagulants, psychotropic drugs, and some alkylating 
anticancer prodrugs (2). In addition, CYP2C9 metabolises 
endogenous substrates such as arachidonic and linolenic 
acid. Updated information regarding the list of allelic 
variants of CYP2C isoforms is available online at 
http://www.imm.ki.se/CYPalleles/.
CYP2C8
The CYP2C8 subfamily accounts for nearly 35 % of 
the total human CYP2C-coded enzymes in the liver and has 
a role in the metabolism of different drugs and endogenous 
compounds (31). Whereas Agúndez et al. (32) claim that 
CYP2C8 is directly involved in the oxidative metabolism 
of NSAIDs such as diclofenac and ibuprofen, Totah et al. 
(33) suggest that CYP2C8 has only a minor or intermediate 
contribution in their metabolism.
The CYP2C8 gene is located on chromosome 10q24, 
spans 31 kb, and shares 74 % of the sequence with the 
CYP2C9 gene (34). According to a recent report (35), at 
the locus of the CYP2C8 gene there are 16 allelic variants. 
These variants are responsible for interindividual and 
interethnic variability in drug response (36), since their 
frequencies vary significantly between races and population 
groups. Clinically the most important variants are 
CYP2C8*2 to *5 (37, 38). The frequencies of the alleles 
*2, *3, and *4 are 0.3, 10.9, and 5.9 in Caucasians and 15.9, 
0.0, 0.41 in Blacks, respectively, while in the Asians these 
variants have not been found, or are extremely low (39, 40). 
Speed et al. (41) reported that 89 % of the CYP2C8*3 
carriers are also the carriers of the CYP2C9*2 variant. These 
authors also suggested that due to a strong linkage 
disequilibrium between these variants, it would be difficult 
to distinguish between associations with CYP2C8 or 
CYP2C9. Although the metabolism of most NSAIDs is 
associated with CYP2C9, CYP2C8 variants may also define 
interindividual differences in the pharmacokinetics of some 
NSAIDs, including ibuprofen and diclofenac (42, 43).
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3The relationship between the CYP2C8 genotype and the 
pharmacokinetics and clinical outcomes of ibuprofen and 
diclofenac therapy
Ibuprofen
A Spanish group of scientists (43) reported results of 
an investigation performed with 355 healthy participants 
who received a single dose of 400 mg ibuprofen. 
Considering that the CYP2C9 genotype could confound the 
association with the pharmacokinetics of ibuprofen, 
participants with the low-activity CYP2C9*3*3 genotype 
were excluded from the study. The clearance of (R)-
ibuprofen was 40 % and 37.1% lower in the participants 
carrying the CYP2C8*3*3 and CYP2C8*1*3 alleles, 
respectively compared to individuals carrying the 
CYP2C8*1*1 genotype (wild type) (p=0.03). This study 
showed that the half-life of (R)-ibuprofen was significantly 
longer in the CYP2C8*3*3 and CYP2C8*1*3 genotype 
carriers compared to wild-type carriers (9 and 4.2 h, 
respectively, vs. 2 h, p˂0.025). Considering that the 
CYP2C8*3 variant was associated with the presence of one 
or two copies of CYP2C9*2 variant in 13 of 16 participants, 
it is difficult to distinguish the effects of either variant on 
the R-ibuprofen metabolism. According to Garcia-Martin 
et al. (44), the clearance of both R- and S-ibuprofen 
clearance in CYP2C8*3 homozygotes was nearly one ninth 
of the clearance in the wild-type homozygotes. The 
CYP2C9*2 variant affected ibuprofen pharmacokinetics 
only in the participants who were also carriers of the 
CYP2C8*3 variant. The authors observed only a limited 
genotype effect on the enantiospecific clearance of 
ibuprofen.
According to Agúndez et al. (32), carriers of the 
CYP2C8*3 and CYP2C9*2 or CYP2C9*3 variants 
manifested an increased risk of gastrointestinal bleeding 
after administration of different NSAIDs, including 
ibuprofen and diclofenac, but could not tell whether it was 
the parent drug or metabolite resulting from alternative 
metabolic pathways to have caused the bleeding.
There is evidence that NSAIDs lower the risk of 
colorectal cancer. The Colorectal Cancer Study Group tested 
the hypothesis that the CYP2C8 and CYP2C9 variants could 
change the protective effect of NSAIDs against colorectal 
cancer in 478 patients with colorectal cancer and 733 
controls (45). While the use of NSAIDs, including ibuprofen 
and aspirin, was confirmed as beneficial in reducing the 
colorectal cancer risk, no variant modified their protective 
effects.
Diclofenac
Dorado et al. (46) investigated the effects of CYP2C8 
polymorphisms on diclofenac metabolism (after a single 
50 mg dose) in 142 healthy Spanish volunteers. The 
participants were genotyped for CYP2C8 and 2C9 variants, 
and the variants analysed for association with the 
concentration of diclofenac and its metabolites. CYP2C8*3 
and 2C8*4 carriers had a higher urinary concentration ratio 
of diclofenac / 5-hydroxy-diclofenac compared to wild-type 
carriers. The authors pointed to the significant overlap 
between the CYP2C8 and CYP2C9 variant allele carriers 
and concluded that it was difficult to estimate the separate 
effects of CYP2C8 polymorphisms on diclofenac 
metabolism. Having in mind that 65 % of diclofenac and 
its metabolites are excreted through the kidneys and 35 % 
are excreted through the liver (47), other polymorphisms 
(such as those of some drug transporters like ABCC2) and 
non-genetic factors (like comedication and comorbidities) 
may affect the metabolism of diclofenac and its excretion.
Reports of hepatotoxic effects of diclofenac (36, 48, 49) 
have raised the question whether the gene variants 
CYP2C8*3, CYP2C9*2,*3 or UGT2B7*2, which code for 
low-activity enzymes, could worsen these effects. Aithal et 
al. (50) found no such association with CYP2C9*2 or *3 
variants, but Daily et al. (36) did. They investigated the 
contribution of the CYP2C8 and UGT2B7 gene variants 
coding for metabolic enzymes (responsible for the 
formation of reactive diclofenac metabolites) and the 
contribution of the variant ABCC2-24C>T of the MRP2 
drug transporter (responsible for the biliary excretion of the 
reactive metabolites). Patients who suffered diclofenac-
induced hepatotoxicity were more frequent carriers of the 
gene variants predisposing for low-activity proteins in 
comparison to the patients who had not developed 
diclofenac-induced hepatotoxicity. They explained that 
increased levels of reactive metabolites may result in higher 
levels of protein-diclofenac adducts and consequently in 
hepatotoxicity. They also observed that the CYP2C8 
variants seemed to contribute less to diclofenac-induced 
liver injury than the allelic variants of the other two genes.
CYP2C9
Gene coding for the CYP2C9 enzyme is located on the 
long arm of chromosome 10 in the region that also contains 
genes for the CYP2C8, 2C18, and 2C19 enzymes (48). The 
enzyme contains 490 amino acids, weighs 55.6 kDa, and 
plays a key role in the metabolism of nearly one hundred 
drugs. So far, 67 allelic variants of the CYP2C9 gene have 
been identified (51).
The relationship between the CYP2C9 genotype and the 
pharmacokinetics and clinical outcomes of ibuprofen and 
diclofenac therapy
Ibuprofen
Several investigations tested if the CYP2C9 *2, *3, and 
CYP2C8*3 allelic variants could reduce ibuprofen 
metabolism and/or clearance (40, 42, 52), predisposing the 
carriers of both allelic variants to a higher risk of adverse 
drug reaction.
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4Kirchheiner et al. (52) were among the first to study the 
kinetics of an oral 600 mg dose of ibuprofen racemate in 
21  hea l t hy  ca r r i e r s  o f  a l l  comb ina t i ons  o f 
the CYP2C9 variants *2 and *3. Data were evaluated using 
a population pharmacokinetic model that integrated 
pharmacogenetic information. According to their results, 
only the 2C9*3 variant affected the pharmacokinetics of 
the racemic and S-ibuprofen. Mean S-ibuprofen clearances 
were 3.25 L h-1, 2.38 L h-1, and 1.52 L h-1 in the carriers of 
the CYP2C9 allele combinations *1/*1, *1/*3, and *3/*3, 
respectively. They did not find any significant effects of the 
CYP2C9*2 variant. In the next step, the authors tested the 
association between the CYP2C9 polymorphisms and the 
formation of thromboxane B2, which is the stable product 
of thromboxane A2 hydrolysis (a potent vasoconstrictor and 
stimulus of platelet aggregation) reflecting cyclooxygenase 
type 1 inhibition. The obtained results suggested that more 
beneficial effects, that is to say, higher inhibition of 
thromboxane formation was observed in the carriers of the 
allelic variants CYP2C9 *1/*3, *2/*3, and *3/*3 than in the 
wild-type carriers (*1/*1). A similar trend was observed for 
prostaglandin E2 (important inflammatory mediator), 
reflecting cyclooxygenase type 2 inhibition. Subjects with 
prolonged ibuprofen availability (poor CYP2C9-mediated 
metabolism) may run a higher risk of adverse drug reactions 
but, on the other hand, they can have better pharmacodynamic 
responses, which can be clinically relevant.
López-Rodríguez et al. (42) studied the effects of the 
CYP2C9 variants on the metabolism of both ibuprofen 
enantiomers in healthy volunteers and found lower 
metabolism of racemic ibuprofen in the 2C9*3 variant 
carriers, resulting in significantly higher area under the 
curve (AUC) and lower clearance than in the 2C9*1 allele 
carriers (p<0.05). As for S-ibuprofen, the clearance was 
45 % lower in the 2C9*3 allele carriers, AUC 87 % higher, 
and half-life 47 % longer than in the 2C9*1 allele carriers. 
R-ibuprofen clearance was also lower in the 2C9*3 variant 
carriers by 30 %. In terms of safety, the CYP2C8*3 carriers 
had fewer adverse events, which was explained with lower 
expression of inducible nitric oxide synthase.
García-Martín et al. (44) analysed genetic factors 
responsible for interindividual differences in the 
pharmacokinetics of ibuprofen and its enantiomers in 
subjects who received a single 400 mg oral dose of racemic 
ibuprofen. The CYP2C9*3 and CYP2C8*3 variants lowered 
the clearance of S-(+)-ibuprofen, whereas the 2C8*3 allele 
was responsible for lower clearance of the R-(-) enantiomer. 
The lowering effect of the CYP2C9*2 variant on ibuprofen 
clearance was observed only in combination with 2C8*3. 
Compared to the wild-type carriers, participants with the 
2C9*1/*2 and 2C8*1/*3 variant combinations (19 % of the 
participants) showed a 65 % clearance whereas the 2C9*3 
and 2C8*3 homozygotes and double heterozygotes had only 
7-27 % of the wild-type ibuprofen clearance (p˂0.001). 
Karaźniewicz-Łada et al. (53) looked for correlations 
between the CYP2C9 and CYP2C8 variants and the 
concentrations of ibuprofen and its metabolites in the 
plasma and urine of healthy volunteers who received a 
single 400 mg dose of racemic ibuprofen. The 2C9*2 and 
*3 and 2C8*3 variant carriers showed lower ibuprofen 
metabolism than other genotypes, and the lowest 
metabolism was observed in a carrier of the CYP2C9*1/*2 
and CYP2C8*1/*3 variant combination. Variant allele 
carriers maintained S-ibuprofen plasma levels for much 
longer, which led to a 40 % higher AUC. They also differed 
from the wild-type carriers in the plasma levels of ibuprofen 
metabolites (C
max
=1.53 vs 2.71 mg L−1 vs for IBP-OH and 
1.66 vs 4.52 mg L−1 for IBP-COOH, respectively). Reduced 
clearance and longer half-life were also observed.
Patent ductus arteriosus (PDA) affects as many as 31 % 
of infants whose birth weight is between 501 and 1500 g 
(54). Ibuprofen is the first-line therapy for PDA with the 
aim to close the ducts through a mechanism that is most 
likely based on prostaglandin inhibition. Durrmeyer et al. 
(55) studied the association between CYP2C9 and CYP2C8 
polymorphisms and response to ibuprofen therapy (ductus 
closure) in extremely preterm neonates diagnosed with 
haemodynamically significant PDA. In multivariate 
analysis the only two factors significantly associated with 
the response to ibuprofen were higher gestational age and 
non Caucasian ethnicity but not CYP2C polymorphism. 
This can be explained by the developmental influence: CYP 
enzymes in the liver of neonates, especially preterm 
neonates, are still maturing, and polymorphisms at that age 
do not have the same impact as in adults. Besides, CYP 
variant frequencies differ significantly between races and 
populations, which can also explain why ethnicity was 
found to be a significant predictor of ibuprofen efficacy. 
Other factors like heterogeneity of studied population and 
sample size could also have affected response to ibuprofen 
and could have masked the effects of CYP polymorphisms.
Diclofenac
Zi et al. (56) investigated in vitro the effects of the 
CYP2C9*2 and CYP2C9*13 variants expressed in yeast 
(and corresponding to the most common gene variants in 
the Chinese population) on the kinetics of diclofenac 
4’-hydroxylation. The in vitro data suggest that these 
variants could lower the clearance of oral diclofenac. They 
also tested the effects of these enzymes on diclofenac 
interactions with nine drugs that inhibit diclofenac 
4’-hydroxylation. The CYP2C9*13 enzyme significantly 
weakened the inhibitory potencies of sulphaphenazole, 
fluvastatin, fluvoxamine, and tranylcypromine. These 
findings can help in co-administration of diclofenac with 
other drugs in individuals carrying the CYP2C9 low-activity 
alleles.
Another group (57) investigated the impact of CYP2C9 
*2 and *3 variants on diclofenac metabolism in vitro and 
in vivo but did not find significant differences in 
4’-hydroxylation of diclofenac between the genotypes. 
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Moreover, the absence of correlation between diclofenac 
hydroxylation and losartan (also a substrate of CYP2C9) 
oxidation in vivo fuelled the scepticism regarding the 
benefits of using diclofenac as a predictor of CYP2C9 
metabolic activity.
Pilotto et al. (58) investigated the effects of the CYP2C9 
genotypes on gastroduodenal toxicity related to diclofenac. 
They studied several NSAIDs, including diclofenac, 
ibuprofen, celecoxib, and naproxen in 26 patients with 
gastroduodenal bleeding who were using NSAIDs and 52 
matched controls. Gastroduodenal bleeding was strongly 
associated with CYP2C9*3 carriers as opposed to non-
carriers (adjusted odds ratio 7.3).
Exploring the risk factors of NSAID-induced small 
intestinal injuries, including diaphragm disease, Ishihara et 
al. (59) tested the role of the CYP2C9*2, *3, and *13 alleles. 
Multivariate analysis indicated that the use of oxicams or 
diclofenac and the presence of comorbidities were 
associated with an increased risk of NSAID-induced small 
intestinal injury (adjusted odds ratio 2.97, p=0.041), but 
other factors including age, sex, concomitant use of proton 
pump inhibitors, indications for NSAID use, duration of 
NSAID use, and the CYP2C9*2, *3 and *13 single 
nucleotide polymorphisms were unrelated. However, the 
use of meloxicam and the CYP2C9*3 variant were 
significantly associated with an increased risk of diaphragm 
disease.
CONCLUSION
Examples provided in this review article suggest that 
knowing which enzymes are involved in ibuprofen and 
diclofenac metabolism may help to predict their 
bioavailability and behaviour.
In this respect, CYP2C9 and CYP2C8 genotyping may 
identify subpopulations of patients who run a higher risk 
of overexposure to the two NSAIDs with adverse 
consequences. Besides CYP enzymes, relevant are phase 
II metabolic pathways, especially UGT enzymes (mainly 
UGT2B7) and drug transporters. Some of the  ABC 
members (like ABCC2) can modulate the hepatobiliary as 
well as renal transport/excretion. Since both pathways are 
coded by polymorphic genes, the need to apply polygenic 
approach in future studies is highly recommended.
Other genetic factors and ethnicity could also mitigate 
the impact of CYP2C genotype on response to ibuprofen 
and diclofenac.
In addition, further research should address factors that 
have received poor coverage so far but that can shed new 
light on the associations between CYP2C polymorphisms 
and NSAID efficacy and toxicity. CYP2C enzymes are 
involved in the metabolism of arachidonic acid to 
biologically active epoxyeicosetrenoic acids (EETs) (60), 
which have potent vasodilator and anti-inflammatory 
properties (61). CYP2C enzymes have also been recognised 
as physiologically relevant in the generation of reactive 
oxygen species (ROS) in vascular endothelial cells, 
affecting thus the vascular tone and homeostasis (62).
Once the relevant genotypes are established, the dose 
can be better predicted and adjusted or another NSAID 
chosen that does not share the same metabolic pathways. 
However, before genotyping is introduced into regular 
clinical practice, more research is needed to answer how 
effective would genotyping be for adjusting doses to the 
individual needs of NSAID users. Current guidelines on 
translating pharmacogenomics into clinical practice seem 
to bring some promise (3). It is important, however, to bear 
in mind that pharmacogenetics/pharmacogenomics is just 
a tool that has to be assessed with other relevant factors that 
may affect drug behaviour, including age, gender, co-
morbidities, and other concomitant drugs (63). This 
approach will improve treatment with NSAIDs while 
avoiding serious adverse effects.
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8Kako polimorfizmi gena citokroma P450 utječu na metabolizam i toksičnost ibuprofena i diklofenaka
Interindividualne razlike u metabolizmu mogu biti važan čimbenik nastanka nuspojava te varijabilnosti u učinkovitosti 
lijeka. Polimorfizmi gena koji kodiraju metaboličke enzime citokrome P450 (CYP) mogu imati značajan učinak na 
metabolizam lijeka i toksičnost. Ovaj pregled donosi spoznaje o tome kako polimorfizam enzima CYP2C8 i CYP2C9 
utječe na bioraspoloživost i kliničke ishode liječenja ibuprofenom i diklofenakom, koji se svrstavaju među najčešće 
propisivane nesteroidne protuupalne lijekove. Hepatotoksičnost i gastrointestinalno krvarenje najčešće su nuspojave 
povezane s utjecajem varijanti CYP2C8*3 i CYP2C9*2*3 na farmakokinetiku ibuprofena i diklofenaka. Na osnovi rezultata 
genotipizacije CYP-a mogu biti prepoznati pacijenti koji imaju povećani rizik od razvoja nuspojava te im je nužno 
prilagoditi dozu lijeka ili odabrati drugi lijek koji ne dijeli isti metabolički put. Osim enzima CYP, značajan utjecaj imaju 
i polimorfizmi gena koji kodiraju fazu II metabolizma, osobito enzimi UGT, te transporteri, poput ABCC2, koji mogu 
modulirati ne samo transport na barijeri jetre i žuči nego i izlučivanje bubrezima. Stoga je u budućim istraživanjima nužan 
poligenski pristup. Prije uvođenja genotipizacije u redovitu kliničku praksu potrebno je provesti daljnja istraživanja koja 
će uključivati veće fenotipski dobro definirane skupine ispitanika za procjenu učinkovitosti ove strategije u poboljšanju 
liječenja ibuprofenom i diklofenakom. Zbog značajne međuetničke razlike u učestalosti polimorfizama gena CYP 
istraživanja treba provesti među različitim rasama i populacijama.
KLJUČNE RIJEČI: CYP2C8; CYP2C9; genotipizacija; hepatotoksičnost; farmakogenetika; farmakogenomika; 
farmakokinetika; nuspojave lijeka
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